An observational study in Torticollis, sponsored by Allergan. Completed at 8 sites in Canada. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2017-03-30.
Sponsored by Allergan · Observational
This is an observational study to assess health-related quality of life in patients with cervical dystonia (dystonie) treated with OnabotulinumtoxinA per routine clinical practice.
319 studies on the registry are indexed under Dystonia; 56 are open to participants now.
This study's enrollment of 62 is close to the median of 60 across 126 observational studies indexed under Dystonia.
Browse Dystonia studies →Allergan is the lead sponsor of 499 studies on the registry; none are open to participants now.
Of its 91 completed or terminated interventional studies of FDA-regulated products, 89 (98%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with Cervical Dystonia (Dystonie)
Exclusion Criteria:
OnabotulinumtoxinA injections at doses and frequencies as determined by the physician in accordance with clinical practice.
Biological: OnabotulinumtoxinA
OnabotulinumtoxinA injections at doses and frequencies as determined by the physician in accordance with clinical practice.
Also known as: botulinum toxin Type A, BOTOX®
Change from Baseline in Cervical Dystonia Impact Profile Questionnaire (CDIP-58) Score
Time frame: Baseline, 96 Weeks
Patient's Global Impression of Change (PGIC) Using a 7-Point Scale
Time frame: Baseline, 96 Weeks
Work Productivity Assessment Using a 10-Item Questionnaire
Time frame: 96 Weeks
Change from Baseline in Hospital Anxiety and Depression Scale (HAD) Score
Time frame: Baseline, 96 Weeks
Reasons for Withdrawal of Treatment
Time frame: 96 Weeks
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Allergan